Get started
Work

1704eTiP SUPRAME: A phase III trial evaluating IMA203 T-cell receptor (TCR) T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma

Year: 2025
Type: article
DOI: 10.1016/j.annonc.2025.08.2331
Authors: D. Schadendorf, W. Alsdorf, R. Amaria, A. Betof Warner, T. Holderried, A. Busse, C. Gebhardt, J.B.A.G. Haanen, J.C. Hassel, S. Klobuch, C. Robert, M. Wermke, S.C. DeVane, S. Hengler, D. Krishna, A. Mayer-Mokler, D. Pankov, C. Britten, J.J. Luke
Institutions: University Medical Center Hamburg-Eppendorf, The University of Texas MD Anderson Cancer Center, Stanford Medicine, Stanford University, University Hospital Bonn, Charité – Universitätsmedizin Berlin, The Netherlands Cancer Institute, National Center for Tumor Diseases, Institut Gustave Roussy, Technische Universität Dresden, Immatics Biotechnologies (Germany), University of Pittsburgh, UPMC Hillman Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Teva Pharmaceutical Industries, American Society of Clinical Oncology, Regeneron Pharmaceuticals, Jazz Pharmaceuticals, Society for Immunotherapy of Cancer, Les Laboratories Pierre Fabre, Mersana Therapeutics, Incyte, Eisai, Astellas Pharma, Swedish Orphan Biovitrum, PharmaMar, Sun Pharma, Ipsen, Genentech, EMD Serono, Daiichi Sankyo Europe
OpenAlex ID: W4415940619
FWCI:
Cites:
Cited by:
Related to: 10